Compare GOTU & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.2M | 511.0M |
| IPO Year | 2019 | 2016 |
| Metric | GOTU | FLGT |
|---|---|---|
| Price | $2.56 | $21.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | ★ 475.6K | 264.9K |
| Earning Date | 08-27-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $15.28 | $2.80 |
| Revenue Next Year | $13.22 | $15.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $13.46 |
| 52 Week High | $3.35 | $31.04 |
| Indicator | GOTU | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 64.07 |
| Support Level | $2.24 | $19.12 |
| Resistance Level | $2.65 | $23.83 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 79.59 | 78.11 |
Gaotu Techedu Inc is a technology-driven education company in China that enables lifelong learning through AI-powered solutions that cultivate interest and drive continuous growth. The Company provides AI-powered, product-led learning solutions for learners from pre-school to adulthood. By combining rare, high-caliber teaching resources with AI-enhanced tools and content, Gaotu creates engaging and effective learning experiences delivered through both online and offline channels. AI and data analytics permeate the Company's operations, adapting content and teaching methods to individual learner needs, improving efficiency, and driving sustained learning progress.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.